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Abstract
Background: Sarcomas are rare, often fatal malignancies of connective tissues that can occur in genetic predisposition
syndromes or result from carcinogen exposure. Hodgkin’s lymphoma (HL) is not known to contribute to any recognised
familial cancer syndrome comprising sarcomas, but is known to be associated with a variety of second cancers,
including sarcomas. This study describes the prevalence of HL in families affected by sarcoma.
Methods: The International Sarcoma Kindred Study (ISKS) is a prospective cohort of 561 families ascertained via a
proband with adult-onset sarcoma. Cancer-specific standardised incidence ratios (SIR) for multiple primary
malignancies in probands were estimated. Clinical characteristics of individuals reporting both sarcoma and HL
were described. Standardised incidence ratios for the occurrence of cancer in ISKS families were also estimated.
Results: Multiple primary cancers were reported in 16% of probands, significantly higher than in the general
population. The risk of HL in probands was increased 15.8-fold (95%CI 7.9-31.6) and increased risks were also seen
for breast cancer (SIR 2.9, 95%CI 1.9-4.4) and thyroid cancer (SIR 8.4, 95%CI 4.2-16.8). In 8 probands with both HL
and sarcoma, the diagnosis of HL preceded that of sarcoma in 7 cases, and occurred synchronously in one case.
Only 3 cases of sarcoma occurred in or close to prior radiotherapy fields. The overall incidence of HL in the ISKS
cohort was not significantly increased by comparison with age- and gender-specific population estimates (SIR 1.63,
95%CI 1.05-2.43), suggesting that the association between HL and sarcomas did not extend to other family
members. The age of onset of non-sarcoma, non-HL cancers in families affected by both HL and sarcoma was
younger than the general population (56.2 y vs 65.6 y, P < 0.0001).
Conclusions: The basis for the association between HL and sarcomas may include the carcinogenic effects of
therapy combined with excellent survival rates for HL. Common risk factors for both may also exist, including both
environmental and heritable factors.
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Background
Cancer is fundamentally a genetic disease. Individual
and familial germline characteristics interact with the
environment to modify the risk of subsequent somatic
genetic changes within cells, the accumulation of which
eventually results in cancer development. Cancers often
cluster in families, and while some of this clustering
may arise from the common environment shared by
families, a significant fraction of cancer risk is
genetically inherited [1]. Dominant Mendelian hereditary
causes are estimated to account for between 1-10% of all
cancer, while moderate risk alleles may account for an
additional portion of heritable cancer risk [2,3]. In the
many pathways contributing to DNA repair systems and
cell cycle control, inherited genetic variation and
somatic changes to minor susceptibility loci may have a
small effect in isolation, but when multiple changes
accumulate, may combine to confer a substantially
increased cancer risk [1].
Sarcomas are rare, often fatal malignancies of connec-
tive tissues whose age of onset is typically younger than
most cancers. Sarcomas account for 15% of childhood
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adults [4]. As a general rule, early age of onset of cancer
increases the likelihood genetic factors are present. Sar-
comas occur more commonly in a number of recognised
hereditary cancer syndromes including Li-Fraumeni syn-
drome, retinoblastoma, neurofibromatosis type 1, Gard-
ner’s and Werner syndromes [5]. Environmental risk
factors include exposure to ionising radiation and to a
less well understood extent, chemical carcinogens [5,6].
Current knowledge about risk factors for sarcomas is
limited. Most studies of heritable risk in sarcomas have
focused on paediatric populations, although 90% of sar-
comas arise over the age of 15 years [4]. Moreover, the
rarity and heterogeneity of sarcomas has presented a
barrier to aetiologic study [7].
Another predictor of heritab l ec a n c e rr i s ki st h ep r e -
sence of multiple primary cancers in individuals [8].
Genetic predisposition and familial aggregation of can-
cers have been shown to be risk factors for the develop-
ment of second primary malignancies within individuals
[9]. Using a prospectively collected cohort of 561
families affected by adult-onset sarcoma, we identified
87 (16%) probands with multiple primary cancers. In
this study we describe the prevalence and types of sec-
ond cancers in probands with adult-onset sarcoma, and
the cancers in their families. An increased risk of second
cancers was observed in probands for: HL, breast cancer
and thyroid cancer. The characteristics of individuals
with a diagnosis of both HL and sarcoma are described
in detail.
Methods
Design
The International Sarcoma Kindred Study (ISKS) is a
prospectively collected familial adult-onset sarcoma
cohort, which began recruitment in July 2009. Probands
were aged at least 15 years when diagnosed with a histo-
logically confirmed sarcoma or an intermediate aggres-
sive connective tissue tumour and were recruited to the
ISKS through sarcoma treatment centres around Austra-
lia. The Database contains family history, clinical, epide-
miological, pathologic and mutation information. The
ISKS Steering Committee granted access to the Data-
base for the purposes of this study under an ethically
approved protocol (PMCC HREC Project 09/11).
Cancer Verification
Wherever possible, reported cancers were verified by
hospital or pathology records, physician correspondence
or through Australian and New Zealand cancer regis-
tries. Validation studies show self-reporting of cancer to
be accurate [10,11] and self-report was considered veri-
fied in this study. Ninety five per cent of cancers in
ISKS probands and 24% of cancers in relatives were
verified. In families reporting an incidence of HL, 100%
of sarcomas in probands and 49% (75/154) of all cancers
were verified. The ISKS attempts to maximise accuracy
of reports by recruiting family members of probands.
This way, ascertainment of family history is strength-
ened and multiple first-degree relatives often provide
cancer reports. Positive predictive value (PPV) and prob-
ability of agreement of reported cancer (with verification
source) in first-degree relatives are greater than 75%,
with many greater than 90%, for most cancer types
including; breast, ovary, prostate, colorectal, pancreas,
lung, lymphoma (PPV 85.7%, 95%CI 71.6-99.8) and leu-
kaemia [11]. Of the 69 cancers in the HL families for
which documented verification was obtained, 98.5% con-
firmed self and, or relative report to be correct.
Of the remaining unverified cancers, 11% ISKS and
14% HL families were first-degree reports and 21% ISKS
and 17% HL families were second-degree reports. 10%
HL family members were overseas and could not be
traced. Many reported cases occurred before cancer
registries collected data or records had been destroyed.
A small number of relatives could not be contacted.
Non-melanoma skin cancers and benign tumours were
excluded from the analyses. All participants provided
written informed consent and ethics approval was
obtained from all relevant research ethics committees.
For cancers without verification and where age data
was unknown, the following protocol was used to obtain
estimates: Date of birth; estimated 25 years before the
date of birth of the oldest child. If an individual had no
children, then date of birth estimated 25 years after
their mother’s date of birth. Age at death; estimated 70
years, or if born after 1951 date of death estimated as
2010. For age at cancer diagnosis; if an individual was
alive and born before 1951, estimated as 60 years. If
deceased, date of diagnosis estimated four years before
their date of death. These rules were applied to estimate
ages in 348 cancers within the ISKS cohort.
Statistical methods
Australian population-based cancer incidence rates spe-
cific for cancer site, age and year of birth (both in five-
year groupings) were obtained for 1982 to 2007 from
the Australian Institute of Health and Welfare [12]. In
ISKS probands, the standardised incidence ratio (SIR)
for each cancer site (excluding sarcomas) was estimated
by comparing the observed number of cancers to the
number expected from population incidence rates. We
then sought to assess the cancer profile in ISKS families
compared to the general population in the same
method. We age-adjusted the Australian population-
based incidence data to correct for the selection bias
inherent in recruiting families for the incidence of sar-
coma, a malignancy of young age of onset. Mean
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sample t-test against Australian population data. 95%
confidence intervals were calculated for all results. Sta-
tistical analyses were performed with Stata version 11
(StataCorp, 2011). All statistical tests were two-sided
and P values < 0.05 were considered nominally statisti-
cally significant.
Results
Overall, 2097 cancers were reported in 561 ISKS
families, and included 561 sarcomas in probands and
1536 other cancers. Multiple primary malignancies were
seen in 87 (16%) probands (see Table 1). In probands,
there was an increased risk of HL (SIR 15.8, 95%CI 7.9-
31.6), breast cancer (SIR 2.9, 95%CI 1.9-4.4) and thyroid
cancer (SIR 8.4, 95%CI 4.2-16.8). There was an
increased risk of cancer other than sarcoma in ISKS
probands and the cumulative risk is shown in Figure 1,
reinforcing the impression that sarcoma is associated
with an increased incidence of other primary
malignancies.
Given the increased risk of HL in probands with sar-
coma, we focused on families affected by HL in more
detail. Twenty two families (4%) reported at least one
case of HL. Of the 22 cases of HL in these families, 8
occurred in probands (6 male, 2 female), and 14 in rela-
tives (4 male, 10 female). To determine whether the
overall incidence of HL and other cancers in the ISKS
cohort was increased, the cancer profile in all 561 ISKS
families was compared to an age- and gender-adjusted
Australian population. An increased standardised inci-
dence ratio for brain (SIR 1.8, 95%CI 1.37-2.33, P <
0.001) and breast (SIR 1.25, 95% CI 1.10-1.41, P <
0.001) cancers was observed. A small, but non-signifi-
cant increase was indicated for HL (SIR 1.63, 95%CI
1.05-2.43). These data indicate that the increased inci-
dence of HL in probands was not reflected in an
increased incidence of HL in family members.
In families affected by both HL and sarcoma, 110 non-
sarcoma, non-HL cancers were reported in 88 people.
The mean age (± standard deviation) at diagnosis of all
110 cancers was 56.2 ± 17.7 years, significantly younger
than the general population (mean 65.6 ± 15.2 years; P
< 0.0001)[13]. Among the 110 cancers, 21 (19%)
occurred before the age of 45 years, compared to 8.6%
of all cancers occurring before 45 years in the Australian
population. Eighteen individuals reported two primary
cancers (eight probands, ten relatives) and two reported
three primary cancers (two probands).
The increased incidence of HL in probands suggests
either a common predisposition to both sarcoma and HL
or carcinogenic effects of therapy for previous cancer
diagnosis. To assess potential effect of prior cancer ther-
apy in the development of sarcomas following HL,
detailed clinical information for the 8 probands affected
by both HL and sarcoma was collected (Table 2). In all
but one case, the HL was diagnosed prior to the sarcoma,
with a median latency of 19 years (range 9 - 32 years).
One case had synchronous diagnoses of HL and sarcoma.
Only three of the eight sarcomas occurred within or adja-
cent to the HL radiotherapy field, while another three
sarcomas arose at sites distant to the radiation field, and
one case was treated with chemotherapy only.
Histological subtypes of HL reported in probands were
nodular sclerosing (5/8), mixed cellularity (2/8) and one
unknown. This is consistent with expected rates of the
spectrum of histological subtypes [14]. One proband
with HL reported a synchronous diagnosis of osteosar-
coma. A variety of subsequent sarcoma subtypes were
reported by seven probands with HL and included: two
fibromyxosarcomas, one leiomyosarcoma, one clear cell
sarcoma of the small bowel, one osteosarcoma, one
malignant fibrous histiocytoma and one pleomorphic
cell sarcoma not otherwise specified. Two probands who
reported both HL and sarcoma also reported malignant
melanomas, without nodal involvement and for which
neither required radiotherapy or chemotherapy. The
Table 1 Primary malignancies in ISKS probands
(excluding sarcoma)
Cancer O E* SIR 95% CI
Hodgkin’s Lymphoma 8 0.51 15.8 7.9-31.6
Thyroid 8 0.95 8.4 4.2-16.8
Breast 21 7.3 2.9 1.9-4.4
Lung 10 4.9 2.1 1.1-3.8
Colorectal 8 6.7 1.2 0.6-2.4
Prostate 6 8.11 0.7 0.3-1.6
*AIHW 1982-2007
CI confidence interval, E expected, O observed, SIR standardised incidence
ratio
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Figure 1 Cumulative risk for all cancers in ISKS probands
(excluding sarcoma). Green = ISKS probands curve Light Blue =
95% confidence interval Grey = AIHW population curve.
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Page 3 of 6Table 2 Hodgkin’s lymphoma and sarcoma in 8 probands
Case Gender HL age
onset
HL
subtype
HL site HL treatment Other primary
malignancy
Sarcoma
age onset
HL - Sarcoma
Latency (years)
Sarcoma subtype Sarcoma
site
Relation to
HL RT
CT RT
1 M 52 Nodular
sclerosing
Neck ABVD 4 cycles MFRT
30.6 Gy
17#
Melanoma L UL
59 y
excision
61 9 Fibromyxosarcoma R thigh Not in field
2 M 44 Nodular
sclerosing
Head/neck NM 6 cycles 35 Gy
20#
- 69 25 Fibromyxosarcoma R UL In field
3* M 34 Mixed
cellularity
R axilla MOPP + ABVD
8 cycles
combination
MRFT
38 Gy
27#
Melanoma UL 47
y
excision
60 26 Pleomorphic cell
sarcoma NOS
L
latissimus
dorsi
In field
4 M 51 Nodular
sclerosing
Chest ABVD IFRT dose
unknown
- 62 11 Leiomyosarcoma Pelvis Not in field
5 F 33 Unknown L axilla CT treatment
records unavailable
RT dose
unknown
- 52 19 Osteosarcoma L
latissimus
dorsi
In field
6 M 19 Nodular
sclerosing
Chest, lungs ABVD 1 cycle - - 19 0 Chondroblastic
osteosarcoma
RL L N oR T
Synchronous
diagnoses
7 F 18 Nodular
sclerosing
Chest,
abdomen,
pelvis
CT - - 27 9 Clear cell sarcoma Small
bowel
No RT
8 M 22 Mixed
cellularity
Neck, chest,
abdomen
CT 36 Gy
18#
- 54 32 Malignant fibrous
histiocytoma
L thigh Not in field
* TP53 mutation positive
ABVD Adriamycin, bleomycin, vinblastine, dacarbazine, CT chemotherapy, F female, Gy gray, IFRT Involved field radiotherapy, HL Hodgkin’s lymphoma, L left, LL lower limb, M male, MFRT mantle field radiotherapy,
MOPP Mustargen, Oncovin, Procarbazine, Prednisone, NM Nitrogen mustard, NOS not otherwise specified, RT radiotherapy, R right, UL upper limb
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6remaining 14 sarcoma probands in the HL families also
reported a variety of histological subtypes, which
included: leiomyosarcoma (4/14), Ewing’s sarcoma (2/
14), and one each of osteosarcoma, fibrosarcoma, clear
cell chondrosarcoma, epithelioid haemangioendothe-
lioma, haemangiosarcoma and synovial sarcoma as well
as two soft tissue sarcomas not otherwise specified. Two
of these 14 probands also reported other cancers. One
reported carcinoma-in-situ of the breast, for which she
had radiotherapy. A lower limb sarcoma developed 10
years later, outside the radiotherapy field. One other
proband reported an earlier diagnosis of acute lympho-
blastic leukaemia (latency 6 years), for which she was
treated with Berlin-Frankfurt-Münster 1995 protocol
chemotherapy, without irradiation. This protocol is asso-
ciated with a cumulative risk for second malignant neo-
plasms of 3.3% after 15 years, but only 1.2% in non-
irradiated patients [15]. Acute myeloid leukaemias and
central nervous system tumours accounted for 70% of
second cancers in this study.
The ISKS cohort is being systematically screened for
mutations in the TP53 gene (manuscript in preparation)
and 3 of the 16 probands in the HL families (including
one who had both a sarcoma and HL) were positive for
germline mutations in TP53 (19%).
Discussion
After familial clustering, second primary malignancies in
individuals are a hallmark of cancer predisposition syn-
dromes [16]. The findings presented here are consistent
with previous reports of an increased rate of sarcomas in
survivors of HL [17,18]. In addition, an increased risk of
breast cancers and thyroid cancers was seen in patients
with sarcoma. The risk of sarcoma development subse-
quent to HL has almost exclusively been attributed to the
effects of radiotherapy, which is known to cause malig-
nancy, but the absolute risk is low [18-23]. In our cases,
five of the eight cases of sarcoma were not attributable to
radiation exposure. Increased radiotherapy dose increases
risk for sarcoma development (RR 26.6, 95%CI 13.3-47.6)
[20], though combination chemotherapy with low-dose
radiotherapy is also associated with increased risk (SIR
88.9, 95%CI 24.2-227.6) [24]. A recent publication also
showed an increased risk for sarcoma due to chemother-
apy plus radiotherapy (SIR 8.9, 95%CI 2.9-20.7), however
found no increased risk for sarcoma development due to
chemotherapy treatment for HL alone [22]. Our study
suggests that radiation exposure does not fully explain
the development of sarcoma, which may instead be
caused by chemotherapy, a common environmental car-
cinogen or a common heritable predisposition.
Shared risk factors for the development of lymphoma
and sarcoma, including acquired immunodeficiency and
herbicide exposure may exist [7]. In a case-control study
assessing risk factors for the development of soft tissue
sarcoma, excess lymphoma and specifically Hodgkin’s
(OR 8.9, 95% CI 1.7-51.2) was noted among sarcoma
relatives [25]. Our data do not support an increased risk
for HL in the ISKS cohort as a whole. However, we
have not excluded the possibility of a common predis-
position, whether hereditary or environmental, to both
HL and sarcoma. Ascertainment biases also underesti-
mate the true rate of cancers in relatives of probands in
family cancer studies [26]. The ISKS partially addresses
this issue by recruiting first-degree relatives who provide
self-reports of cancers. In addition, cancers were verified
through access to population registries and by obtaining
pathology reports. While our data do not support com-
mon predisposition to HL and sarcoma, the one case of
synchronous HL and sarcoma cannot be explained by
the carcinogenic effects of prior treatment of HL,
whether radiotherapy or chemotherapy.
The pattern of second primary cancers in sarcoma-
affected probands is of interest. Breast cancer is the
most commonly reported primary cancer associated
with development of subsequent radiation-associated
soft tissue sarcoma [27,28]. The median latency period
between radiation exposure and sarcoma development
has been reported between 8.4 and 10 years [27,28].
Given breast cancer incidence in the population is sig-
nificantly higher than HL, we expected a greater propor-
tion of ISKS probands reporting previous breast cancer.
We considered an ascertainment bias for survival of the
primary cancer, but the overall survival of patients with
breast cancer is comparable with HL [29]. The incidence
of breast cancer and brain cancer in families with sarco-
mas is reminiscent of the Li-Fraumeni Syndrome. As in
our cohort, the incidence of lymphoma in a US-based
case control study of 24 families with Li-Fraumeni Syn-
drome was not increased [30]. None of the cancer pedi-
gree patterns in the 22 HL families in the ISKS fit the
classic criteria for Li-Fraumeni Syndrome [30], or any
other familial cancer syndrome. However, the rate of
TP53 mutations in HL probands (19%) was higher than
that reported in the only previous study of TP53 muta-
tions in sarcoma-affected populations [8].
Conclusions
We have presented findings that suggest an association
between the development of sarcomas and HL. The
increase in risk for HL occurring in sarcoma probands
was not adequately explained by prior therapies, and did
not extend to relatives.
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